

Michel Jadoul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1134379/publications.pdf>

Version: 2024-02-01

190
papers

10,433
citations

30047

54
h-index

37183

96
g-index

195
all docs

195
docs citations

195
times ranked

10265
citing authors

#	ARTICLE	IF	CITATIONS
1	Diseases of the Aorta and Kidney Disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Cardiovascular Research, 2022, 118, 2582-2595.	1.8	6
2	Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review. American Journal of Kidney Diseases, 2022, 79, 717-727.	2.1	42
3	APOL1 Renal Risk Variants and Sickle Cell Trait Associations With Reduced Kidney Function in a Large Congolese Population-Based Study. Kidney International Reports, 2022, 7, 474-482.	0.4	7
4	Dynamics of spreading of SARS-CoV-2 in a Belgian hemodialysis facility: The importance of the analysis of viral strains. Journal of Medical Virology, 2022, 94, 1481-1487.	2.5	3
5	Humoral responses to BNT162b2 SARS-CoV-2 and hepatitis B vaccines are associated in patients on maintenance hemodialysis: a single-center experience in Belgium. CKJ: Clinical Kidney Journal, 2022, 15, 363-365.	1.4	1
6	Letter Regarding "Nephrophtisis Is an Important Differential Diagnosis of Nonspecific Interstitial Nephritis in Adults". Kidney International Reports, 2022, 7, 1139.	0.4	1
7	Characteristics, practices, and outcomes in a Belgian cohort of incident home hemodialysis patients: A 6-year experience. Hemodialysis International, 2022, , .	0.4	2
8	Aortic stenosis in patients with kidney failure: Is there an advantage for a PD-first policy?. Peritoneal Dialysis International, 2021, 41, 158-167.	1.1	8
9	A Longitudinal, 3-Month Serologic Assessment of SARS-CoV-2 Infections in a Belgian Hemodialysis Facility. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 613-614.	2.2	35
10	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2021, 99, 34-47.	2.6	195
11	Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD. Clinical and Translational Science, 2021, 14, 299-309.	1.5	18
12	Extremely rapid stone formation in cystinuria: look out for dietary supplements!. CKJ: Clinical Kidney Journal, 2021, 14, 1694-1696.	1.4	1
13	Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in Nephrology Practice Across Countries. Kidney International Reports, 2021, 6, 437-448.	0.4	19
14	Citric Acid-Containing Dialysate and Survival Rate in the Dialysis Outcomes and Practice Patterns Study. Kidney360, 2021, 2, 666-673.	0.9	2
15	Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide. CKJ: Clinical Kidney Journal, 2021, 14, 1977-1979.	1.4	3
16	The great help of a virus in the fight against bacteria!. Journal of Nephrology, 2021, 34, 965-966.	0.9	1
17	Protocadherin 7-Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 1249-1261.	3.0	92
18	Serum uric acid, disease severity and outcomes in COVID-19. Critical Care, 2021, 25, 212.	2.5	22

#	ARTICLE	IF	CITATIONS
19	Impact of rural versus urban setting on kidney markers: a cross-sectional study in South-Kivu, DR Congo. BMC Nephrology, 2021, 22, 234.	0.8	2
20	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	2.6	103
21	Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab. CKJ: Clinical Kidney Journal, 2021, 14, 2132-2133.	1.4	8
22	Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2021, 100, 35-48.	2.6	26
23	Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease. Acta Clinica Belgica, 2021, , 1-10.	0.5	2
24	Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine in a Multicenter Cohort of Nursing Home Residents Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases, 2021, 78, 766-768.	2.1	14
25	Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International, 2021, 100, 516-526.	2.6	156
26	Granulomatous vasculitis after the AstraZeneca anti-â€SARS-CoV-2 vaccine. Kidney International, 2021, 100, 706-707.	2.6	37
27	HCV Can and Should Be Eliminated From Dialysis Units. American Journal of Kidney Diseases, 2021, 78, 487-488.	2.1	5
28	Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline. American Journal of Kidney Diseases, 2021, 77, 152.	2.1	3
29	Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort. Nephrology Dialysis Transplantation, 2021, 36, 918-926.	0.4	16
30	Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline. Clinical Gastroenterology and Hepatology, 2020, 18, 2158-2167.	2.4	9
31	Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney International, 2020, 97, 163-174.	2.6	213
32	<scp>HCV</scp> in the haemodialysis population: Treat now or later?. Journal of Viral Hepatitis, 2020, 27, 233-234.	1.0	1
33	Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study. American Journal of Kidney Diseases, 2020, 76, 624-635.	2.1	30
34	SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney International, 2020, 98, 1296-1307.	2.6	173
35	Prevalence and Risk Factors of CKD in South Kivu, Democratic Republic of Congo: A Large-Scale Population Study. Kidney International Reports, 2020, 5, 1251-1260.	0.4	10
36	Absence of SARS-CoV-2 in the effluent of peritoneal dialysis patients. Peritoneal Dialysis International, 2020, 40, 499-503.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Nomenclature for kidney function and disease—executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. <i>European Heart Journal</i> , 2020, 41, 4592-4598.	1.0	44
38	Nomenclature for kidney function and disease: executive summary from a KDIGO consensus conference. <i>Nature Reviews Nephrology</i> , 2020, 16, 427-428.	4.1	2
39	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2020, 97, 1117-1129.	2.6	407
40	Non-invasive Quantification of Fat Deposits in Skeletal Muscle Predicts Cardiovascular Outcome in Kidney Failure. <i>Frontiers in Physiology</i> , 2020, 11, 130.	1.3	10
41	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 861-876.	2.6	126
42	Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era. <i>Transplantation Proceedings</i> , 2020, 52, 815-822.	0.3	8
43	Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 937-948.	2.2	47
44	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , 2020, 5, 1129-1138.	0.4	14
45	Etiologies, Clinical Features, and Outcome of Oxalate Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 1503-1509.	0.4	34
46	The Case Severe acute hypocalcemia in a patient on hemodialysis. <i>Kidney International</i> , 2020, 97, 619-620.	2.6	1
47	The authors reply. <i>Kidney International</i> , 2020, 97, 615.	2.6	1
48	The authors reply. <i>Kidney International</i> , 2020, 97, 421-422.	2.6	0
49	<p>Estimating the Fraction of First-Year Hemodialysis Deaths Attributable to Potentially Modifiable Risk Factors: Results from the DOPPS<p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 51-60.	1.5	10
50	Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2020, 98, 294-309.	2.6	254
51	Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 679-689.	2.1	56
52	Sodium polystyrene sulfonate: still news after 60 years on the market. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1455-1458.	0.4	11
53	Current CKD Definition Takes into Account Both Relative and Absolute Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 447-448.	3.0	11
54	Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations. <i>African Journal of Nephrology</i> , 2020, 23, 159-168.	0.1	0

#	ARTICLE	IF	CITATIONS
55	The choice of the assay for measuring albumin has a major impact on routine laboratory values. <i>Kidney International</i> , 2019, 96, 248.	2.6	2
56	Intestinal angioedema from angiotensin converting enzyme inhibitor. <i>Kidney International</i> , 2019, 96, 798.	2.6	2
57	Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries. <i>BMC Nephrology</i> , 2019, 20, 169.	0.8	6
58	Self-reported Urine Volume in Hemodialysis Patients: Predictors and Mortality Outcomes in the International Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2019, 74, 425-428.	2.1	11
59	Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. <i>Kidney International</i> , 2019, 95, 939-947.	2.6	89
60	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2019, 393, 1937-1947.	6.3	408
61	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2019, 171, 496.	2.0	20
62	Hepatitis C virus and the kidney. <i>Nature Reviews Nephrology</i> , 2019, 15, 73-86.	4.1	60
63	The patient with metabolic alkalosis. <i>Acta Clinica Belgica</i> , 2019, 74, 34-40.	0.5	13
64	Locking Hemodialysis Catheters With Trimethoprim-Ethanol-Ca-EDTA to Prevent Bloodstream Infections: A Randomized, Evaluator-blinded Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 130-136.	2.9	10
65	Influence of hemodialysis on pramipexole pharmacokinetics: Lessons from two cases and literature review. <i>Clinical Nephrology Case Studies</i> , 2019, 7, 11-16.	0.3	2
66	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	1.0	186
67	Genotype and Outcome After Kidney Transplantation in Alport Syndrome. <i>Kidney International Reports</i> , 2018, 3, 652-660.	0.4	22
68	The prevention of hepatitis C virus transmission to hemodialysis patients and staff members. <i>Hemodialysis International</i> , 2018, 22, S104-S109.	0.4	10
69	Fractures in CKD patients: action plans should not overlook the prevention of falls!. <i>Kidney International</i> , 2018, 93, 1247.	2.6	5
70	Taurolidine-based lock solutions for hemodialysis catheters: the enthusiasm should be tempered. <i>Kidney International</i> , 2018, 93, 1015-1016.	2.6	6
71	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018, 94, 663-673.	2.6	72
72	Impact of a clinical decision support system for drug dosage in patients with renal failure. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1225-1233.	1.0	23

#	ARTICLE	IF	CITATIONS
73	The Case Severe hypokalemia complicated by a syncope. <i>Kidney International</i> , 2018, 94, 225-226.	2.6	3
74	Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1782-1789.	0.5	33
75	The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. <i>Seminars in Liver Disease</i> , 2018, 38, 181-192.	1.8	185
76	Superior vena cava stenosis in haemodialysis patients with a tunnelled cuffed catheter: prevalence and risk factors. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2227-2233.	0.4	19
77	DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. <i>Kidney International</i> , 2018, 94, 589-598.	2.6	24
78	An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw023.	0.4	11
79	Dialysis-related Amyloidosis: Is It Gone or Should It Be?. <i>Seminars in Dialysis</i> , 2017, 30, 193-196.	0.7	18
80	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 620-640.	0.4	133
81	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2756-2767.	3.0	448
82	ANCA vasculitis in a patient with Alport syndrome: a difficult diagnosis but a treatable disease!. <i>BMC Nephrology</i> , 2017, 18, 105.	0.8	2
83	Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 287-297.	2.2	119
84	Quiz. <i>American Journal of Kidney Diseases</i> , 2017, 69, A8-A11.	2.1	1
85	Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective. <i>Blood Purification</i> , 2017, 43, 206-209.	0.9	23
86	The Use of a Multidimensional Measure of Dialysis Adequacy—Moving beyond Small Solute Kinetics. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 839-847.	2.2	62
87	Should all dialysis patients with hepatitis C be treated? If so, before or after kidney transplantation?. <i>Seminars in Dialysis</i> , 2017, 30, 395-397.	0.7	8
88	Enteric hyperoxaluria in chronic pancreatitis. <i>Medicine (United States)</i> , 2017, 96, e6758.	0.4	17
89	Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2017, 69, 266-277.	2.1	123
90	Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy—case report and literature review. <i>BMC Nephrology</i> , 2017, 18, 282.	0.8	5

#	ARTICLE	IF	CITATIONS
91	MP385RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR PRESCRIPTION PATTERNS IN HEMODIALYSIS PATIENTS: RESULTS FROM THE INTERNATIONAL DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS). Nephrology Dialysis Transplantation, 2017, 32, iii569-iii569.	0.4	0
92	Long-term Outcome of Kidney Recipients Transplanted for Aristolochic Acid Nephropathy. Transplantation, 2016, 100, 416-421.	0.5	8
93	The Case Subcutaneous abdominal calcified nodules and severe hyperphosphatemia. Kidney International, 2016, 89, 1171-1172.	2.6	1
94	CutaneousMycobacterium chelonaeinfection distal to the arteriovenous fistula. CKJ: Clinical Kidney Journal, 2016, 9, 735-738.	1.4	0
95	Haemodialysis is a major risk factor for infective endocarditis. Lancet, The, 2016, 388, 339-340.	6.3	16
96	Phosphate binder pill burden, patient-reported nonadherence, and mineral bone disorder markers: Findings from the DOPPS. Hemodialysis International, 2016, 20, 38-49.	0.4	101
97	Acute kidney injury is a powerful independent predictor of mortality in critically ill patients: a multicenter prospective cohort study from Kinshasa, the Democratic Republic of Congo. BMC Nephrology, 2016, 17, 118.	0.8	27
98	Moderator's View: Buttonhole cannulation of arteriovenous fistulae: great caution is warranted: Table A1.. Nephrology Dialysis Transplantation, 2016, 31, 530-533.	0.4	10
99	Î² ₂ microglobulin amyloidosis: an update 30 years later. Nephrology Dialysis Transplantation, 2016, 31, 507-509.	0.4	29
100	Association Studies of Calcium-Sensing Receptor (CaSR) Polymorphisms with Serum Concentrations of Glucose and Phosphate, and Vascular Calcification in Renal Transplant Recipients. PLoS ONE, 2015, 10, e0119459.	1.1	15
101	Buttonhole Cannulation Is Not Associated with More AVF Infections in a Low-Care Satellite Dialysis Unit: A Long-Term Longitudinal Study. PLoS ONE, 2015, 10, e0142256.	1.1	12
102	Renovascular acute renal failure precipitated by extracorporeal shock wave lithotripsy for pancreatic stones. CKJ: Clinical Kidney Journal, 2015, 8, 426-429.	1.4	1
103	The fate of triaged and rejected manuscripts. Nephrology Dialysis Transplantation, 2015, 30, 1947-1950.	0.4	9
104	Con: Frequent haemodialysis for all chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 23-27.	0.4	7
105	The Case Bilateral severe mechanical joint pain in the lower limbs in a hemodialysis patient. Kidney International, 2015, 88, 207-208.	2.6	3
106	Opponent's comment. Nephrology Dialysis Transplantation, 2015, 30, 22-23.	0.4	0
107	Towards eradication of hepatitis C virus from dialysis units. Lancet, The, 2015, 386, 1514-1515.	6.3	17
108	Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrology Dialysis Transplantation, 2014, 29, 1633-1638.	0.4	68

#	ARTICLE	IF	CITATIONS
109	Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo. <i>BMC Nephrology</i> , 2014, 15, 146.	0.8	17
110	Interferon- α -induced thrombotic microangiopathy in patients with chronic myelogenous leukemia. <i>Kidney International</i> , 2014, 85, 213-214.	2.6	4
111	Impact of liver fibrosis staging in hepatitis C virus (HCV) patients with kidney failure. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1108-1110.	0.4	10
112	Sailing Between Scylla and Charybdis: The High Serum K ⁺ “Low Dialysate K Quandary. <i>Seminars in Dialysis</i> , 2014, 27, 463-471.	0.7	11
113	What are the Causes of the Ill Effects of Chronic Hemodialysis?. <i>Seminars in Dialysis</i> , 2014, 27, 16-18.	0.7	2
114	Potassium-Binding Resins: Associations with Serum Chemistries and Interdialytic Weight Gain in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2014, 39, 252-259.	1.4	35
115	Intravenous Hydration (With or Without Rosuvastatin) Should Remain the Cornerstone of the Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 332.	1.2	6
116	Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. <i>Journal of Nephrology</i> , 2014, 27, 707-711.	0.9	15
117	What are the Management Issues for Hepatitis C in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2014, 27, 449-451.	0.7	3
118	Hepatitis C Infection Is Very Rarely Treated among Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2013, 38, 405-412.	1.4	132
119	Modifiable Practices Associated with Sudden Death among Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 765-774.	2.2	145
120	Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 640-646.	0.4	45
121	Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-of-week mortality. <i>Kidney International</i> , 2012, 81, 1108-1115.	2.6	85
122	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1924-1930.	0.4	43
123	A Decade After the KDOQI CKD Guidelines: A Perspective From Europe. <i>American Journal of Kidney Diseases</i> , 2012, 60, 743-744.	2.1	1
124	Meta-Analysis: The Impact of Nutritional Status on the Immune Response to Hepatitis B Virus Vaccine in Chronic Kidney Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1366-1372.	1.1	27
125	The prevalence and detection of chronic kidney disease (CKD)-related metabolic complications as a function of estimated glomerular filtration rate in the oldest old. <i>Archives of Gerontology and Geriatrics</i> , 2012, 54, e419-e425.	1.4	7
126	Progression of Coronary Artery Calcification and Thoracic Aorta Calcification in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2012, 59, 258-269.	2.1	98

#	ARTICLE	IF	CITATIONS
127	Infectious Complications Following Conversion to Buttonhole Cannulation of Native Arteriovenous Fistulas: A Quality Improvement Report. <i>American Journal of Kidney Diseases</i> , 2011, 57, 442-448.	2.1	92
128	Anti-HBs antibody persistence following primary vaccination with an investigational AS02v-adjuvanted hepatitis B vaccine in patients with renal insufficiency. <i>Hum Vaccin</i> , 2011, 7, 913-918.	2.4	15
129	The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2362-2369.	0.4	44
130	Serum Fetuin-A Levels Are Associated with Vascular Calcifications and Predict Cardiovascular Events in Renal Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 974-985.	2.2	57
131	Aortic Stiffness and Central Wave Reflections Predict Outcome in Renal Transplant Recipients. <i>Hypertension</i> , 2011, 58, 833-838.	1.3	96
132	Preparing renal replacement therapy in stage 4 CKD patients referred to nephrologists: a difficult balance between futility and insufficiency. A cohort study of 386 patients followed in Brussels. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 220-226.	0.4	51
133	Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1424-1428.	0.4	25
134	The Case of Multiple-organ failure in a dialysis patient with pericarditis. <i>Kidney International</i> , 2011, 80, 787-788.	2.6	2
135	Estimating GFR in the oldest old: does it matter what equation we use?. <i>Age and Ageing</i> , 2011, 40, 401-405.	0.7	13
136	Coronary artery calcification: a strong predictor of cardiovascular events in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3773-3778.	0.4	47
137	The decades-long fight against HBV transmission to dialysis patients: slow but definite progress. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2047-2049.	0.4	16
138	Catheter-related blood stream infections (CRBSI): a European view. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1753-1756.	0.4	68
139	Physical exercise among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS): correlates and associated outcomes. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3050-3062.	0.4	251
140	The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1834-1838.	0.4	62
141	The Burden of Amputation Among Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2009, 54, 680-692.	2.1	69
142	Non-invasive diagnosis and monitoring of chronic kidney disease by reverse iontophoresis of urea in vivo. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 1077-1082.	2.0	28
143	A mysterious 'homesickness'. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 371-372.	1.4	0
144	Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1666-1672.	0.4	123

#	ARTICLE	IF	CITATIONS
145	Consistent Aspirin Use Associated with Improved Arteriovenous Fistula Survival among Incident Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1373-1378.	2.2	34
146	New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2431-2432.	0.4	2
147	Identification of current smokers among renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1974-1978.	0.4	22
148	Towards the prevention of bone fractures in dialysed patients?. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3377-3380.	0.4	12
149	Prevalence and Determinants of Coronary and Aortic Calcifications Assessed by Chest CT in Renal Transplant Recipients. <i>American Journal of Nephrology</i> , 2007, 27, 329-335.	1.4	38
150	Persistence of Î²2-Microglobulin Amyloidosis 20 Years After Successful Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2007, 50, 167-168.	2.1	5
151	Assessment of the "Skin Reservoir" of Urea by Confocal Raman Microspectroscopy and Reverse Iontophoresis in vivo. <i>Pharmaceutical Research</i> , 2007, 24, 1897-1901.	1.7	35
152	Improving Outcomes for Dialysis Patients in the International Dialysis Outcomes and Practice Patterns Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 246-255.	2.2	92
153	Peripheral Arterial Disease in Patients With End-Stage Renal Disease. <i>Circulation</i> , 2006, 114, 1914-1922.	1.6	229
154	Falls in hemodialysis patients: Prospective study of incidence, risk factors, and complications. <i>American Journal of Kidney Diseases</i> , 2005, 45, 148-153.	2.1	146
155	Large Genomic Rearrangements in the Hepatocyte Nuclear Factor-1Î (TCF2) Gene Are the Most Frequent Cause of Maturity-Onset Diabetes of the Young Type 5. <i>Diabetes</i> , 2005, 54, 3126-3132.	0.3	236
156	Acute Liver Failure with Renal Impairment Related to the Abuse of Senna Anthraquinone Glycosides. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1353-1357.	0.9	96
157	Sevelamer and pharmacokinetics of cyclosporin A after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 661-661.	0.4	2
158	Influence of a Pre-Dialysis Education Programme (PDEP) on the mode of renal replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1842-1847.	0.4	171
159	Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. <i>Kidney International</i> , 2004, 65, 2335-2342.	2.6	356
160	Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2004, 44, 34-38.	2.1	269
161	Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 898-903.	0.4	77
162	The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 904-909.	0.4	160

#	ARTICLE	IF	CITATIONS
163	Drug interaction between sevelamer and cyclosporin. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 515-515.	0.4	16
164	Determinants of serum levels of surfactant proteins A and B and Clara cell protein CC16. <i>Biomarkers</i> , 2003, 8, 461-471.	0.9	43
165	Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 826-829.	0.4	26
166	The importance of a histology-based diagnosis of interstitial nephropathy in two patients with renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 440-442.	0.4	11
167	Cytotoxic therapy of lupus nephritis: recent developments. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 955-957.	0.4	9
168	Autosomal-dominant periodic fever with AA amyloidosis: Novel mutation in tumor necrosis factor receptor 1 gene Rapid Communication. <i>Kidney International</i> , 2001, 59, 1677-1682.	2.6	39
169	Pathological Aspects of β_2 -Microglobulin Amyloidosis. <i>Seminars in Dialysis</i> , 2001, 14, 86-89.	0.7	18
170	Aristolochic acid nephropathy in a Chinese patient: Time to abandon the term "Chinese herbs nephropathy". <i>American Journal of Kidney Diseases</i> , 2001, 38, E26.	2.1	92
171	Ten ways to ruin or market your oral scientific communication. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2119-2123.	0.4	1
172	Spironolactone and congestive heart-failure. <i>Lancet</i> , The, 2000, 355, 1369-1370.	6.3	22
173	Histological characteristics of sternoclavicular β_2 -microglobulin amyloidosis and clues for its histogenesis. <i>Kidney International</i> , 1999, 55, 1983-1990.	2.6	41
174	Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress". <i>Kidney International</i> , 1999, 55, 2487-2492.	2.6	68
175	Interferon- γ -associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. , 1999, 85, 2669-2670.		11
176	Urothelial lesions in Chinese-herb nephropathy. <i>American Journal of Kidney Diseases</i> , 1999, 33, 1011-1017.	2.1	276
177	Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian multicenter study. <i>Kidney International</i> , 1998, 53, 1022-1025.	2.6	157
178	Molecular analysis of GB virus C isolates in Belgian hemodialysis patients. <i>Journal of Medical Virology</i> , 1998, 55, 118-122.	2.5	11
179	Prevalence of histological β_2 -microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. <i>Kidney International</i> , 1998, 54, 956-959.	2.6	55
180	Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. <i>Kidney International</i> , 1997, 51, 880-887.	2.6	119

#	ARTICLE	IF	CITATIONS
181	Histological prevalence of β_2 -microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. <i>Kidney International</i> , 1997, 51, 1928-1932.	2.6	146
182	Histological beta-2-microglobulin amyloidosis 10 years after a successful renal transplantation. <i>American Journal of Kidney Diseases</i> , 1996, 27, 888-890.	2.1	12
183	Low molecular weight proteinuria in Chinese herbs nephropathy. <i>Kidney International</i> , 1995, 48, 1571-1576.	2.6	79
184	Hepatitis C virus. <i>Lancet</i> , The, 1995, 345, 189-191.	6.3	12
185	Should Hemodialysis Patients with Hepatitis C Virus Antibodies Be Isolated?. <i>Seminars in Dialysis</i> , 1995, 8, 1-3.	0.7	17
186	Chinese herbs nephropathy: A clue to Balkan endemic nephropathy?. <i>Kidney International</i> , 1994, 45, 1680-1688.	2.6	247
187	Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. <i>Kidney International</i> , 1994, 45, 1689-1696.	2.6	100
188	Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. <i>Kidney International</i> , 1993, 44, 1322-1326.	2.6	183
189	β_2 -Microglobulin Amyloidosis in a Patient Treated Exclusively by Continuous Ambulatory Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 1990, 15, 86-88.	2.1	40
190	NORFLOXACIN AND CYCLOSPORINEA SAFE COMBINATION. <i>Transplantation</i> , 1989, 47, 747-748.	0.5	9